{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117666","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.424510+00:00","generated_at":"2026-06-21T21:05:47.142039+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MedTech Acquisition Corp. to merge with TriSalus Life Sciences for $220M in stock","bullets":["Merger consideration: $220M paid entirely in MTAC common stock valued at $10.00 per share.","Closing conditions include MTAC having at least $60M in available cash and net tangible assets ≥$5M.","Sponsor agrees to forfeit 2,187,500 shares and subject 3,125,000 shares to vesting restrictions.","Non-binding term sheet for up to $50M of 8.0% senior secured convertible notes from Magnetar Capital.","TriSalus stockholders subject to 365-day lock-up; lock-up ends earlier if stock hits $12 for 20 of 30 days after 150 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117666","json":"https://secwatch.observer/filing/0001104659-22-117666.json","markdown":"https://secwatch.observer/filing/0001104659-22-117666.md","text":"https://secwatch.observer/filing/0001104659-22-117666.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922117666/0001104659-22-117666-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922117666/tm2230343d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:05:47.142039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8c4d9942187637d5d318fb74261c301a6bf613a1","claim":"TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with MedTech Acquisition Corporation and MTAC Merger Sub, Inc. valued at $220,000,000 (effective 2022-11-11).","evidence_excerpt":"On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (\" MTAC \"), entered into an Agreement and Plan of Merger (the \" Merger Agreement \") with MTAC Merger Sub, Inc., a Delaware corporation and direct, wholly owned subsidiary of MTAC (\" Merger Sub \"), and TriSalus Life Sciences, Inc., a Delaware corporation (\" TriSalus \")","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465922117666/0001104659-22-117666-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"MedTech Acquisition Corporation and MTAC Merger Sub, Inc."},{"label":"Value","value":"$220,000,000"},{"label":"Effective","value":"2022-11-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}